Maintenance strategies in stage IV non-small-cell lung cancer (NSCLC): In which patients, with which drugs?

Annals of Oncology

Volumn 25, Issue 7, 2014, Pages 1283-1293

  Polo, V ^a,b   Besse, Benjamin ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Continuation maintenance; Early second line; Non small cell lung cancer; Switch maintenance

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; GEFITINIB; GEMCITABINE; IFOSFAMIDE; LOMUSTINE; METHOTREXATE; MITOMYCIN; NAVELBINE; PACLITAXEL; PAZOPANIB; PEMETREXED; PLACEBO; PLATINUM DERIVATIVE; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; VINBLASTINE; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ANEMIA; ARTICLE; CANCER STAGING; CHEMORADIOTHERAPY; DRUG APPROVAL; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG TOLERANCE; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FATIGUE; GENE MUTATION; HEALTH CARE ACCESS; HEMOPTYSIS; HUMAN; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MAINTENANCE CHEMOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PATIENT CARE; PATIENT PREFERENCE; PATIENT SELECTION; PERIPHERAL NEUROPATHY; PHARMACOGENETICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; PATHOLOGY; PATHOPHYSIOLOGY;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; QUALITY OF LIFE;

EID: 84903715511     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt529     Document Type: Article

References (51)

1. NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008; 26: 4617-4625.
2. Scagliotti GV, De Marinis F, Rinaldi M et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002; 20: 4285-4291.
3. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92-98.
4. Fossella F, Pereira JR, von Pawel J et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group. J Clin Oncol 2003; 21: 3016-3024.
5. Kelly K, Crowley J, Bunn PA, Jr et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001; 19: 3210-3218.
6. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
7. Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239-246.
8. Shaw AT, Kim DW, Nakagawa K et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Eng J Med 2013; 368: 2385-2394.
9. Soria JC, Mauguen A, Reck M et al. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol 2013; 24: 20-30.
10. Alberola V, Camps C, Provencio M et al. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced nonsmall- cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol 2003; 21: 3207-3213.
11. Ohe Y, Ohashi Y, Kubota K et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 2007; 18: 317-323.
12. Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543-3551.
13. Soon YY, Stockler MR, Askie LM et al. Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. J Clin Oncol 2009; 27: 3277-3283.
14. Buccheri GF, Ferrigno D, Curcio A et al. Continuation of chemotherapy versus supportive care alone in patients with inoperable non-small cell lung cancer and stable disease after two or three cycles of MACC. Results of a randomized prospective study. Cancer 1989; 63: 428-432.
15. Socinski MA, Schell MJ, Peterman A et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 2002; 20:1335-1343.
16. Belani CP, Barstis J, Perry MC et al. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol 2003; 21: 2933-2939.
17. Brodowicz T, Krzakowski M, Zwitter M et al.; Central European Cooperative Oncology Group (CECOG). Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced nonsmall cell lung cancer: a phase III trial. Lung Cancer 2006; 52: 155-163.
18. Belani CP, Waterhouse DM, Ghazal H et al. Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2010; 28(Suppl):(Abstr 7506).
19. Pérol M, Chouaid C, Pérol D et al. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced nonsmall- cell lung cancer. J Clin Oncol 2012; 30: 3516-3524.
20. Paz-Ares L, de Marinis F, Dediu M et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 2012; 13: 247-255.
21. Paz-Ares LG, de Marinis F, Dediu M et al. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 2013; 31: 2895-902.
22. Barlesi F, Scherpereel A, Rittmeyer A et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous nonsmall- cell lung cancer: AVAPERL (MO22089). J Clin Oncol 2013; 31: 3004-11.
23. Rittmeyer A, Scherpereel A, Gorbunova VA et al. Effect of maintenance bevacizumab (Bev) plus pemetrexed (Pem) after first-line cisplatin/Pem/Bev in advanced nonsquamous non-small cell lung cancer (nsNSCLC) on overall survival (OS) of patients ( pts) on the AVAPERL (MO22089) phase III randomized trial. J Clin Oncol 2013; 31(Suppl): 8014.
24. Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial -INTACT 1. J Clin Oncol 2004; 22: 777-784.
25. Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 2. J Clin Oncol 2004; 22: 785-794.
26. Herbst RS, Prager D, Hermann R et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23:5892-5899.
27. Gatzemeier U, Pluzanska A, Szczesna A et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007; 25:1545-1552.
28. Scagliotti G, Novello S, von Pawel J et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 1835-1842.
29. Paz-Ares LG, Biesma B, Heigener D et al. Phase III, randomized, double-bind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol 2012; 30: 3084-3092.
30. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
31. Reck M, von Pawel J, Zatloukal P et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous nonsmall- cell lung cancer: AVAil. J Clin Oncol 2009; 27: 1227-1234.
32. Reck M, von Pawel J, Zatloukal P et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010; 21:1804-1809.
33. Pirker R, Pereira JR, Szczesna A et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009; 373: 1525-1531.
34. Lynch TJ, Patel T, Dreisbach L et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010; 28: 911-917.
35. Patel J, Socinski MA, Garon EB et al. A randomized, open-label, phase 3, superiority study of pemetrexed (Pem) + carboplatin (Cb) + bevacizumab (B) followed by maintenance Pem + B versus paclitaxel (Pac) + Cb + B followed by maintenance B in patients ( pts) with stage IIIB or IV non-squamous non-small cell lung cancer (NS-NSCLC). J Thorac Oncol 2012; 7(Suppl): LBPL1.
36. Pfister DG, Johnson DH, Azzoli GC et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003. J Clin Oncol 2004; 22: 330-353.
37. Peters S, Adjei AA, Gridelli C et al. Metastatic non-small-cell lung cancer (NSCLC):ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23(Suppl 7): vii56-vii64.
38. Azzoli CG, Baker S, Jr, Temin S et al. American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009; 27: 6251-6266.
39. Smith IE, O'Brien MER, Talbot DC et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 2001; 19: 1336-1343.
40. von Plessen C, Bergman B, Andresen O et al. Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. Br J Cancer 2006; 95: 966-973.
41. Park JO, Kim SW, Ahn JS et al. Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non-small-cell lung cancer. J Clin Oncol 2007; 25: 5233-5239.
42. Westeel V, Quoix E, Moro-Sibilot D et al.; French Thoracic Oncology Collaborative Group (GCOT). Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer. J Natl Cancer Inst 2005; 97: 499-506.
43. Fidias PM, Dakhil SR, Lyss AP et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009; 27: 591-598.
44. Ciuleanu T, Brodowicz T, Zielinski C et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009; 374: 1432-1440.
45. Cappuzzo F, Ciuleanu T, Stelmakh L et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebocontrolled phase 3 study. Lancet Oncol 2010; 11: 521-529.
46. Miller VA, O'Connor P, Soh C et al. A randomized, double-blind, placebocontrolled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2009; 27(Suppl): LBA8002.
47. Kabbinavar FF, Miller VA, Johnson BE et al. Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2010; 28(Suppl): 7526.
48. Takeda K, Hida T, Sato T et al. Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer:results of a West Japan Thoracic Oncology Group Trial (WJTOG0203). J Clin Oncol 2010; 28: 753-760.
49. Gaafar RM, Surmont VF, Scagliotti GV et al. A double-blind, randomised, placebocontrolled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03). Eur J Cancer 2011; 47: 2331-2340.
50. Zhang L, Ma S, Song X et al. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. Lancet Oncol 2012; 13: 466-475.
51. Garassino M, Rulli E, Marabese M et al. Prognostic and predictive role of KRAS mutations in patients with advanced non-small cell lung cancer treated with docetaxel or erlotinib as second line treatment in the TAILOR trial. Presented at the European Cancer Congress 2013, Amsterdam, Netherlands, 27 September-1 October 2013 (Abstr 32).